Clinical Impact of Parathyroid Autofluorescence Visualization During Thyroid Surgery

Sponsor
Hôpital Européen Marseille (Other)
Overall Status
Completed
CT.gov ID
NCT02889952
Collaborator
Assistance Publique Hopitaux De Marseille (Other)
297
19

Study Details

Study Description

Brief Summary

This Before-and-after Controlled Study study evaluates the clinical impact of parathyroid autofluorescence visualization using near infrared light (NIR) during total thyroidectomy (TT).

It compares two groups of consecutive patients who underwent TT associated or not to lymph node dissection (LND) with and without intraoperative use of NIR, by the same surgeon.

Condition or Disease Intervention/Treatment Phase
  • Device: Near infrared camera (NIR)

Detailed Description

Total thyroidectomy (TT) is responsible for postoperative hypocalcemia in 20-30% of patients, which is definitive in 1-4% of operated patients (1).

This complication is mainly due to surgery-induced parathyroid dysfunction, which could be improved by a better intraoperative identification of the parathyroids.

Intraoperative parathyroid auto-fluorescence visualization (without any dye injection) using near infrared light (NIR) is an emerging technique, which allows correct identification of normal parathyroids in almost all cases (2), but the clinical impact of NIR is unknown.

The main objective of this study is to assess the impact of intraoperative use of NIR camera on postoperative hypocalcemia. Secondary objectives are to assess the impact of NIR on the visualization, autotransplantation and inadvertent resection rates during TT.

The investigators compare 2 groups of patients operated by one surgeon during 2 consecutive but distinct periods (before and after the use of NIR) with control groups operated by another surgeon during the same periods. This study is observational since there was no predefined protocol nor sample size calculation of study groups prior to data collection.

Study Design

Study Type:
Observational
Actual Enrollment :
297 participants
Time Perspective:
Cross-Sectional
Official Title:
Parathyroid Autofluorescence Visualization During Thyroid Surgery: Impact on Postoperative Hypocalcemia
Study Start Date :
Jan 1, 2015
Actual Primary Completion Date :
May 1, 2016
Actual Study Completion Date :
Aug 1, 2016

Arms and Interventions

Arm Intervention/Treatment
NIR-

All consecutive patients (n=174) who underwent conventional total thyroidectomy (TT)+/- lymph node dissection (LND) without the use of NIR - parathyroid identification was done by naked eye only- by surgeon 1, from January 2015 to January 2016 (period 1)

NIR

All consecutive patients (n=63) who underwent conventional total thyroidectomy (TT)+/- lymph node dissection (LND) with intraoperative use of NIR - surgical field was examined with NIR before any thyroid dissection- by surgeon 1, from February 2016 to May 2016 (period 2)

Device: Near infrared camera (NIR)
Surgical field was examined with NIR, during a few minutes (<5') with room lights switched off, to avoid parasite lights, then conventional open thyroidectomy was resumed conventionally. Real-time images, evocative of autofluorescent parathyroids, were checked visually. NIR consisted of a 750 nm class 1 laser excitation, with a power <20mW/cm2 (5 times less than the limit of 100mw/cm2, fixed by the international norm IEC 60601-2-41). It was provided by the Fluobeam® camera, which was inserted into a sterile cover and hold at a 15-20 cm distance from the patient. The system has an FDA 510(k) authorization for clinical use in parathyroid surgery and a European Community certification (Class 1 device).
Other Names:
  • Fluobeam® system (Fluoptics®, Grenoble, France)
  • Control1

    Patients (n=30) patients randomly selected among the patients who underwent TT+/- LND without the use of NIR, by another surgeon in the unit (surgeon 2), during period 1.

    Control2

    Patients (n=30) patients randomly selected among the patients who underwent TT+/- LND without the use of NIR, by surgeon 2, during period 2.

    Outcome Measures

    Primary Outcome Measures

    1. Postoperative hypocalcemia [6 months]

      Postoperative day 1 and day 2 corrected calcemia(hypocalcemia when calcemia <2mmol/l). If hypocalcemia, calcium is measured at 1 month and 6 months

    Secondary Outcome Measures

    1. number of identified parathyroids [immediate (intraoperative)]

    2. number of autotransplantated parathyroids [immediate (intraoperative)]

      when parathyroids are impossible to preserve in situ, they are fragmented and inserted in the sternocleidomastoid muscle

    3. number of inadvertently resected parathyroids [within 15 days after surgery (time to complete pathology examination)]

      When parathyroids are found on the thyroid specimen during pathology examination, they are called 'inadvertently resected'

    Other Outcome Measures

    1. number of parathyroids identified by NIR before naked eye [immediate (intraoperative)]

      in NIR group only

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • All patients who underwent one-stage total thyroidectomy, associated or not to lymph node dissection (TT +/- LND)
    Exclusion Criteria:
    • Combined parathyroid and thyroid disease (including patients with enlarged parathyroids incidentally found during surgery and resected)

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Hôpital Européen Marseille
    • Assistance Publique Hopitaux De Marseille

    Investigators

    • Principal Investigator: Fares BENMILOUD, MD, Hopital Europeen Marseille

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Fares BENMILOUD, Dr, Hôpital Européen Marseille
    ClinicalTrials.gov Identifier:
    NCT02889952
    Other Study ID Numbers:
    • ParaFluo1
    First Posted:
    Sep 7, 2016
    Last Update Posted:
    Sep 7, 2016
    Last Verified:
    Aug 1, 2016
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Keywords provided by Fares BENMILOUD, Dr, Hôpital Européen Marseille
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 7, 2016